Showing results (1-10 of 94) with videos related to
Sort By:
Pageof 10
Journal of the American College of Cardiology|March 1, 2002
Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospectsMetin Avkiran, Michael S MarberExperimental and Clinical Cardiology|August 4, 2009
Factors determining heterogeneity in coronary collateral development: A clinical perspectivePier D Lambiase, Michael S MarberJournal of Pharmacological and Toxicological Methods|February 28, 2004
An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heartSimon G Fisher, Michael S MarberExperimental Physiology|October 16, 2012
Advancements in pressure-volume catheter technology - stress remodelling after infarctionJames E Clark, Michael S MarberJournal of Molecular and Cellular Cardiology|November 11, 2010
The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failureMichael S Marber, Beth Rose, Yibin WangDrug Discovery Today. Disease Mechanisms|February 1, 2011
Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in pointMichael S Marber, Jeffery D Molkentin, Thomas ForceBiochemical Pharmacology|October 13, 2004
Specificity of action of bisindolylmaleimide protein kinase C inhibitors: do they inhibit the 70kDa ribosomal S6 kinase in cardiac myocytes?Neil A Roberts, Michael S Marber, Metin AvkiranPharmacology & Therapeutics|September 4, 2007
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart diseaseJames E Clark, Negin Sarafraz, Michael S MarberCurrent Opinion in Pharmacology|February 22, 2008
Targeting p38-MAPK in the ischaemic heart: kill or cure?Rekha Bassi, Richard Heads, Michael S Marber, et al.Heart (British Cardiac Society)|January 4, 2011
Troponins: redefining their limitsJames O Baker, Johannes Reinhold, Simon Redwood, et al.Pageof 10